Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Type 2 Diabetes
 More »

  • Mass Spec Provides Peek into PTMs
    ... development of diabetes and the related diabetic cardiovascular diseases," Dr. ... Depending on the tissue type used, generally 20-30 N-glycan species are detected simultaneously. ...
    5-15-2013
  • Cash-Strapped Unigene Gets $1M Boost from Nordic
    Unigene Laboratories and Nordic Bioscience have entered into an equity transfer and exclusive license agreement involving three metabolic peptide analogs for type 2 diabetes, ...
    5-9-2013
  • BMS Partners Again with Ambrx, in Up-to-$112M-and-Up ADC Collaboration
    One agreement covered the Fibroblast Growth Factor 21 (FGF-21) protein, for potentially treating type 2 diabetes; the other focused on the Relaxin hormone, for potentially treating ...
    5-3-2013
  • Merck Launches Up To $430M Diabetes Collaboration with Abide
    Abide Therapeutics to discover, develop, and commercialize small molecule therapies designed to treat type 2 diabetes and other metabolic diseases by targeting serine hydrolases. ...
    5-2-2013
  • Merck Joins Pfizer to Develop Type 2 Diabetes Drug
    up to develop and commercialize Pfizer's ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor being evaluated for type 2 diabetes. ...
    4-29-2013
  • Cytomics for Personalized Heart Health
    ... Proof-of-concept studies at CytoVas show that high levels of microparticles and endothelial progenitor cells differ significantly between patients with type 2 diabetes (a model for ...
    4-15-2013
  • Axe Falls on 1,000 at Lilly
    ... The pharma giant has four diabetes treatments in its pipeline, three of them in Phase III: LY2189265 (dulaglutide), a once-weekly treatment for type 2 diabetes; and LY2963016 (new ...
    4-12-2013
  • Yale Wins $10 Million Grant for Novel Immunobiology Research
    chronic illnesses, including cardiovascular disease, type 2 diabetes, autoimmune diseases, asthma and allergies, neurodegenerative diseases such as Alzheimer's disease, and cancer. ...
    4-9-2013
  • BMS Shores Up R&D after Trial Failure, Plavix Patent Loss
    ... billion in 2011. BMS will announce first-quarter 2013 results on April 25. Forxiga, approved in Europe for type 2 diabetes, was co-developed and co-commercialized with AstraZeneca. ...
    4-8-2013
  • Top 20 Best-Selling Drugs Approved and Launched During 2012
    (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol. ...
    4-4-2013
  • Epigenetics Opens New Avenues for DNA Research
    ... For example, 32 loci associated with Crohn's disease explain approximately 20% of the heritability for this condition, and about 47 loci linked to type 2 diabetes and glycemic ...
    4-1-2013
  • Scaling Up Peptide Drugs
    adults with short bowel syndrome; and Bydureon (an extended-release version of Byetta, with the active ingredient exenatide, Amylin/Alkermes) for patients with type 2 diabetes. ...
    4-1-2013
  • Personalized Medicine: Why We Are So Excited
    ... We know even less about the factors, which may determine whether a person has an increased risk of developing a particular disease. Is "type-2 diabetes" a single homogeneous ...
    3-8-2013
  • Small Firms Look Optimistically to Future
    ... to look at microbial interactions and are conducting preclinical research on obesity and type 2 diabetes. Last year, we got blank stares when we discussed the gut microbiome. ...
    3-1-2013
  • Top 20 Best-Selling Drugs of 2012
    ... Indication(s): Once-daily type 2 diabetes treatment 2012 sales: $4.086 billion 2011 sales: $3.324 billion % Change: 22.9% Q4 2012 sales: $1.134 billion, up 18.1% from $960 million ...
    3-1-2013
  • More »

    Journal Articles

  • Anthropometric Measurements and Diabetes Mellitus: Clues to the...
    Harold E. Bays, Kathleen M. Fox, Susan Grandy
    Metabolic Syndrome and Related Disorders
    Respondents diagnosed with type 2 diabetes mellitus (T2DM; n?=?3825) and without T2DM (n = 13,327) self-reported their weight and height, WC, and HC. Results: T2DM men and women ...
  • Hypertensive Treatment in Patients With Metabolic Syndrome
    David Siegel, Arthur L.M. Swislocki
    Metabolic Syndrome and Related Disorders
    Metabolic Syndrome and Related Disorders The prevalence of obesity, hypertension, and type 2 diabetes mellitus-in other words, the metabolic syndrome-is increasing in the United ...
  • Prevalence and Determinants of Hyperuricemia in Middle-Aged,...
    Raquel Villegas, Yong-Bing Xiang, Qiuyin Cai, Sergio Fazio, MacRae Linton, Honglan Li, Tom Elasy, Wei Zheng, Xiao Ou Shu
    Metabolic Syndrome and Related Disorders
    Abstract Background: Hyperuricemia is associated with metabolic syndrome and has emerged as a marker for both type 2 diabetes and cardiovascular disease. We estimated the ...
  • Antihypertensive Treatment, High Triglycerides, and Low High...
    Poul Suadicani, Hans Ole Hein, Finn Gyntelberg
    Metabolic Syndrome and Related Disorders
    Methods: This was a 16-year follow up of 2,986 men 53-75 years old ... Potential risk factors were type of baseline medication, blood pressure, diabetes, fasting serum triglycerides ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll